Rates of stimulant use disorder (StUD) in the U.S. are rising, as are consequences associated with stimulant use in combination with opioids. Over the past decade, overdose death rates have increased three-fold for cocaine and twelve-fold for other stimulants—including methamphetamine, amphetamine, and prescription stimulants. In addition to overdose deaths, StUD is associated with a broad range of serious and long-term health problems, including cardiac, psychiatric, and dental complications. Injection stimulant use increases the risk of contracting human immunodeficiency virus (HIV), viral hepatitis, and other infectious diseases such as infective endocarditis. The rising rate and potency of stimulants in the U.S. drug supply, low prices, and potential contamination of stimulants with synthetic opioids such as fentanyl, and adulterants such as levamisole are expected to exacerbate risks. Taken together, these factors position StUD as a major threat to public health.
ASAM and AAAP partnered to develop a national clinical guideline on the management of StUD. The guideline aims to assist clinicians in treating individuals with StUD, as well as individuals experiencing stimulant intoxication or withdrawal, and persons who are at high risk of developing StUD. The guideline covers StUD assessment, harm reduction guidance, management of acute complications, and behavioral and pharmacological treatment approaches for StUD. This session will summarize the key components, recommendations and applications of the clinical practice guideline on StUD including approaches for vulnerable populations.
Larissa Mooney, MD, Chairperson, Presenter
Larissa Mooney, M.D. is a Professor of Clinical Psychiatry and Director of the Addiction Psychiatry Division in the Department of Psychiatry and Biobehavioral Sciences at UCLA. She is the Director of the UCLA-VA Addiction Psychiatry Fellowship Program and previously served as the Section Chief for Substance Use Disorders at the Greater Los Angeles VA. Dr. Mooney is the Immediate Past President of the American Academy of Addiction Psychiatry (AAAP), a Distinguished Fellow of the American Psychiatric Association (APA), and a Fellow of the American Society of Addiction Medicine (ASAM). She is one of two Principal Investigators for the Greater Southern California Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network.
Brian Hurley, MD, Presenter
Brian Hurley, MD, MBA, DFASAM, FAPA is an addiction physician and the Medical Director of the Bureau of Substance Abuse Prevention and Control in the Los Angeles County Department of Public Health and a volunteer assistant clinical professor of addiction medicine in the UCLA Department of Family Medicine. He is the President of the American Society of Addiction Medicine and gives presentations around the world regarding addiction medicine and motivational interviewing. He is a Primary Investigator for an award to the Los Angeles County Department of Public Health from the Substance Abuse Mental Health Services Administration's first Harm Reduction Grant Program and the Centers for Disease Control Overdose to Action:LOCAL award to Los Angeles County. Additionally, he is the grant lead for three Medications for Addiction Treatment Access Points projects funded by the Sierra Health Foundation supporting access to medications for addiction treatment across Los Angeles County. He is a member of the Motivational Interviewing Network of Trainers.
Kevin Sevarino, MD, PhD, Presenter
Dr. Sevarino earned his MD, CM at McGill Faculty of Medicine and PhD in molecular biology at the University of Connecticut Health Center. After an internship in Internal medicine, he trained in psychiatry in the dual clinical/basic research tract at the Yale University School of Medicine. For six years thereafter, he was PI on NIH grants examining neurobiological mechanisms underlying cocaine dependence, and since then has transitioned to being a clinician-educator who remained active in clinical research as a member of the MIRECC VA Team in studies examining new treatments for substance use disorders. He was Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System from Dec. 2004 through Aug. 2017. He was consulting psychiatrist to Gaylord Hospital, Wallingford from 1999 – 2009, and again 2017-2023. He now works as per diem psychiatrist at Hartford Healthcare – Rushford. His particular expertise is in treatment of the dually-diagnosed and non-opiate pharmacological management of chronic pain. He is Associate Clinical Professor of Psychiatry, Yale University School of Medicine. He was subspecialty certified in Psychosomatic Medicine by the American Board of Psychiatry and Neurology from 2009 - 2019, in Addiction Medicine by the American Board of Addiction Medicine from 2010 - 2020, and currently in Addiction Medicine by the American Board of Preventative Medicine. Dr. Sevarino serves as Medical Director for the American Academy of Addiction Psychiatry (AAAP), and is a past president of that organization. He was Course Director for the AAAP Board Review Course in Addictions, which developed into the Addictions and Their Treatment Course, from 2007 - 2015. He currently co-directs AAAP’s Advanced Addiction Psychopharmacology course.